Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences' stock has experienced significant movements driven by clinical updates and financial news. The stock price saw a substantial increase of 944.53% between May 5, 2025, and May 1, 2026. In March 2026, Inhibrx reported its Fourth Quarter and Fiscal Year 2025 financial results, showing a net loss of $140.1 million for FY25, and announced plans to submit a BLA for ozekibart and interim ORR data for INBRX-106. In April 2026, the stock experienced notable positive movement, including a 7.61% gain as of April 24, 2026, and a significant increase of 36.88% on April 22, 2026. News emerged that cancer therapies from Inhibrx were reportedly drawing big pharma interest, and the stock hit record highs. The stock was up 46.3% following new ozekibart colorectal cancer data and FDA plans. In December 2025, Citizens reiterated a "Market Perform" rating on INBX stock, citing concerns about limited data disclosures and a lack of management communication. Inhibrx secured an additional $75 million in financing through an amended loan agreement to strengthen its financial position in March 2026.

As a clinical-stage biopharmaceutical company, Inhibrx Biosciences, Inc. does not currently have commercially available products or services that would exhibit traditional demand seasonality. Its business is focused on research and development, with revenue generation primarily from potential licensing activities and financing. Therefore, demand seasonality for its products and services is not applicable at this stage of its operations.

Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates for life-threatening conditions, operating within the Healthcare sector and Biotechnology industry. The company utilizes proprietary protein engineering platforms to create therapeutic candidates, including Ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma and INBRX-106 for metastatic solid tumors.

Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. While its headquarters are in the U.S., the company conducts clinical trials globally, with the ChonDRAgon study for ozekibart enrolling patients across 67 different sites worldwide.

Inhibrx Biosciences' brand reputation has been primarily influenced by its clinical trial progress and analyst perceptions. The company has received a consensus "Hold" rating from analysts, with an average rating score of 2.33. Positive clinical trial results, such as ozekibart meeting its primary endpoint in the ChonDRAgon study, have positively impacted its reputation. Concerns raised by analysts regarding "limited data disclosures and lack of management communication" have also been noted.

Inhibrx Biosciences, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 8.50% to 19.32% of the company's stock is owned by institutional investors, 9.70% by insiders, and 10.82% to 70.98% by public companies and individual investors. Major institutional owners include Perceptive Advisors Llc, Viking Global Investors Lp, Morgan Stanley, Sanofi, HighTower Advisors, LLC, BlackRock, Inc., Vanguard Group Inc, and Sofinnova Investments, Inc.